Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-07-06 17:11:31 ET · period of report 2026-06-30 · accession 0002001011-26-000108 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-06 17:11 | 2026-06-30 | LGND | Reardon Andrew | CLO, Sec | J - Other | $160.71 | +132 | 41.5K | +0.3% | +$21.2K |
| DT | 2026-07-06 17:11 | 2026-07-01 | LGND | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +5,000 | 46.5K | +12% | +$261.4K |
| DMT | 2026-07-06 17:11 | 2026-07-01 | LGND | Reardon Andrew | CLO, Sec | S - Sale+OE | $313.28 | -5,000 | 41.5K | -11% | -$1.57M |
| DT | 2026-07-06 17:11 | 2026-07-01 | LGND | Reardon Andrew | CLO, Sec | M - OptEx | $0.00 | -5,000 | 34.4K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | J | A | 132 | $160.71 | 41,514 | D | — | — | (F1) These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 2 | Common | Common Stock | 2026-07-01 | M | A | 5,000 | $52.27 | 46,514 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. |
| 3 | Common | Common Stock | 2026-07-01 | S | D | 396 | $308.99 | 46,118 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $308.6300 to $309.6000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-07-01 | S | D | 104 | $310.20 | 46,014 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $310.0100 to $310.2100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-07-01 | S | D | 1,119 | $311.72 | 44,895 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F5) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $311.0900 to $312.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-07-01 | S | D | 1,081 | $312.28 | 43,814 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F6) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $312.1050 to $312.5300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2026-07-01 | S | D | 700 | $313.46 | 43,114 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F7) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $313.1300 to $314.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8 | Common | Common Stock | 2026-07-01 | S | D | 100 | $314.58 | 43,014 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F8) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $314.3100 to $314.5900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 9 | Common | Common Stock | 2026-07-01 | S | D | 900 | $315.78 | 42,114 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F9) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $315.4400 to $316.2600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 10 | Common | Common Stock | 2026-07-01 | S | D | 600 | $317.15 | 41,514 | D | — | — | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F10) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $316.7000 to $317.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 11 | Derivative | Employee Stock Option (right to buy) | 2026-07-01 | M | D | 5,000 | $0.00 | 34,444 | D | $52.27 · — to 2032-08-01 | 5,000 Common Stock | (F2) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. (F11) The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. |